Healthcare stocks can provide growth and consistent returns through a variety of market cycles. Eli Lilly has a storied ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless”.

An astonishing fact about the GLP-1 meds that are helping millions lose weight: Tirzepatide, the active ingredient in ...

The U.S. stock market sank from record heights as Wall Street sifted through mixed developments on everything from the ...

Berkshire reported $13.485 billion in operating profit from its wholly owned businesses in the third quarter, a 34% increase ...

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

These growth stocks are highly profitable and evolving in their respective industries. Eli Lilly is famed for its weight-loss medications, but it is more than just a GLP-1 play. MercadoLibre is a ...

Scripps Research in La Jolla announce a new clinical trial that will assess the effectiveness of using drugs approved for diabetes treatment and weight loss to treat long COVID-19, the debilitating ...

Get the latest S&P 500 healthcare stock winners & losers, major earnings beats, profit forecasts, and legal news for key companies.

Tirzepatide, a medication sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown impressive results in helping people avoid developing diabetes. A new study found that it ...